Group items tagged

HIV continues to have a disproportionate impact on specific populations, particularly racial and ethnic minorities and gay and #bisexual men. However, with increasing access to effective HIV prevention and diagnosis, HIV has become a manageable chronic health condition, enabling people living with HIV to lead long and healthy lives. For More Information Website: https://drpounders.com/ or Call Us at 214-520-8833

Opportunistic infections (OIs) are infections that occur more often or are more severe in people with weakened immune systems than in people with healthy immune systems. People with weakened immune systems include people living with HIV. For people with HIV, the best protection against OIs is to take HIV medicines every day. For more information visit our site: https://drpounders.com/ or Call us: 214-520-8833

People who don't receive HIV treatment will typically proceed into three stages. But HIV medication can reduce or halt the rise of the disease. With the improvements in treatment, advance to Stage 3 is now less than in the initial days of HIV. For More Information Visit Our Website https://drpounders.com/ or Call Us at 214-520-8833

In its first, the National Institute for Health and Care Excellence has recommended the use of long-acting injectable treatment for HIV-1 infection in adults, making around 13,000 people eligible for treatment with cabotegravir with rilpivirine in England. The new treatment aims to keep the number of virus particles in the blood so low that it cannot be detected or transmitted between people. Current treatment for HIV‑1 is lifelong antiretroviral tablets taken each day. Use of cabotegravir with rilpivirine is recommended when there is no evidence tosuspect viral resistance, and no previous failure of other anti-HIV-1 medicines. "Clinical trial results show that cabotegravir with rilpivirine is as effective as oralantiretrovirals at keeping the viral load low," NICE stated. Both are administered as two separate injections every two months, after an initial oral (tablet) lead-in period.

Britain's GlaxoSmithKline will receive $1.25 billion (about £921 million) from Gilead Sciences as part of a settlement between its HIV medicines unit and the US-based drugmaker, ending a long-drawn patent dispute. The settlement, announced by GSK on Tuesday (February 1), relates to Gilead's antiretroviral drug Biktarvy, a medicine used to check the AIDS-causing virus, which GSK said in 2018 infringed on its unit ViiV Healthcare's dolutegravir and other similar compounds. HIV medicines developed by ViiV, in which Pfizer and Japan's Shionogi also hold small stakes, are a major part of GSK's plan to support its lagging pharmaceuticals business as it readies to spin off its consumer healthcare arm. The payment is expected to be made in the first quarter this year, London-listed GSK said. Gilead will also pay a 3 per cent royalty until 2027 on sales of Biktarvy and on future US sales of any product containing its main component.

British drugmaker GSK has signed deals with three companies allowing them to make inexpensive generic versions of its long-acting HIV preventive medicine for use in lower-income countries, where the majority of new HIV cases occur. The injected drug cabotegravir is approved by regulators in Britain and the United States. Last July, GSK announced a program with the United Nations-backed healthcare organisation, the Medicines Patent Pool, aiming to get poor countries access to new HIV therapies far earlier than they did for previous HIV medicines. During the HIV/AIDs epidemic in Africa in the 1990s and early 2000s, in which many millions of people died, treatments used widely in wealthy countries were unavailable on the continent. GSK said last year the new program could result in the generic form of its injection being available in lower-income countries beginning in 2026. The drugmaker's HIV treatment division, ViiV Healthcare, said in a statement on Wednesday it had issued voluntary licenses - waiving intellectual property rights - to Aurobindo, Cipla and Viatris, which will manufacture the generic versions of injectable cabotegravir.

In partnership with the Prescription Charges Coalition (PCC), the Royal Pharmaceutical Society (RPS) has taken a significant step by urging political leaders to abolish prescription charges for individuals with long-term conditions. Tase Oputu, Chair of the RPS England Pharmacy Board, signed an open letter on Thursday, calling on party leaders to address this pressing issue. The letter emphasises the outdated nature of the current exemption list, which forces individuals with chronic conditions like Parkinson's, cystic fibrosis, and HIV to bear the cost of their essential medications. It urges party leaders to urgently review and update the exemption list to ensure equitable access to necessary medicines. "Nobody should face a financial barrier to accessing the medicines they need," Oputu stated.